Table 1 Baseline characteristics of the study cohorts.

From: Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor–targeting therapy

 

C-FS

(N = 14)

mCRPC

(N = 50)

p-value

Age,

Median (IǪR)

60

(53.25 - 63.75)

77

(69 - 81)

<0.0001

BMI,

Median (IǪR)

25

(24.1 - 27.04)

26.49

(24.61 – 28.07)

0.13

PSA,

Median (IǪR)

4.53

(3.2 - 5.57)

2.1

(1.07 - 5.79)

0.23

Gleason, n (%)

 ≤7

 >7

Not available

/

18 (36%)

25 (50%)

7 (14%)

 

FU (y)

/

3.02

(2.18 - 4.14)

 
  1. Data are reported as median and interquartile range (IQR) for continuous variables and as number (percentage) for categorical variables. PSA: prostate-specific antigen. FU follow-up duration in years. NA not available.
Back to article page